Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 14,599 | 22,850 | 21,607 | 28,787 | 53,076 |
| TOTAL | $15,561 | $23,576 | $22,521 | $30,154 | $56,584 |
| Non-Current Assets | |||||
| PPE Net | 60 | 82 | 88 | 2 | 24 |
| Other Non-Current Assets | 312 | 322 | 41 | 0 | 215 |
| TOTAL | $372 | $403 | $129 | $2 | $239 |
| Total Assets | $15,933 | $23,980 | $22,650 | $30,156 | $56,824 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 714 | 1,352 | 1,670 | 843 | 1,773 |
| Accrued Expenses | 2,051 | 2,009 | 2,186 | 2,358 | 5,353 |
| TOTAL | $2,764 | $3,361 | $4,386 | $3,201 | $7,317 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 529 | N/A | N/A |
| Other Non-Current Liabilities | 727 | 1,311 | 1,311 | 1,311 | 0 |
| TOTAL | $727 | $1,311 | $1,311 | $1,311 | $N/A |
| Total Liabilities | $3,492 | $4,672 | $5,697 | $4,512 | $7,317 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 11,452 | 5,492 | 5,430 | 3,732 | 1,099 |
| Common Shares | 8 | 6 | 4 | 3 | 1 |
| Retained earnings | -333,641 | -321,042 | -308,083 | -293,796 | -181,134 |
| Other shareholders' equity | -10,635 | -10,627 | -10,611 | -10,623 | -10,359 |
| TOTAL | $12,442 | $19,308 | $16,954 | $25,644 | $49,507 |
| Total Liabilities And Equity | $15,933 | $23,980 | $22,650 | $30,156 | $56,824 |